Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-07-11
2000-08-01
Burke, Julie
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 13, 514 14, 514 15, 514 16, 514 17, 514 18, 530317, 530324, 530325, 530326, 530327, 530328, 530329, 530330, 530331, A61K 3812, C07K 512
Patent
active
060967072
ABSTRACT:
Cyclic peptides comprising three colinear amino acids, arginine-lysine-lysine (RKK) are provided that bind to the integrin .alpha.2I domain and are potent inhibitors of its interaction with collagens I and IV and laminin-1. Methods of using such peptides to block integrin function and to inhibit cell migration are also provided.
REFERENCES:
patent: 5179007 (1993-01-01), Jarvis et al.
patent: 5627263 (1997-05-01), Ruoslahti et al.
Bergelson, J.M. et al., "The Integrin VLA-2 Binds Echovirus 1 and Extracellular Matrix Ligands by Different Mechanisms," J. Clin. Invest. 92(1):232-239 (Jul., 1993).
Busk, M. et al., "Characterization of the Integrin .alpha.v.beta.6 as a Fibronectin-binding Protein," J. Biol. Chem. 267(9):5790-5796 (Mar., 1992).
Cardarelli, P.M. et al., "The Collagen Receptor .alpha.2.beta.1, from MG-63 and HT1080 Cells, Interacts with a Cyclic RGD Peptide," J. Biol. Chem. 267(32):23159-23164 (Nov., 1992).
De Luca, M. et al., "Jararhagin and Jaracetin: Novel Snake Venom Inhibitors of the Integrin Collagen Receptor, .alpha..sub.2 .beta..sub.1, " Biochem. Biophys. Res. Comm. 206(2):570-576 (Jan., 1995).
Drake, S.L. et al., "Structural Features of Fibronectin Synthetic Peptide FN-C/H II, Responsible for Cell Adhesion, Neurite Extension, and Heparan Sulfate Binding," J. Biol. Chem. 268(21):15859-15867 (Jul., 1993).
Eble, J.A. et al., "The .alpha.1.beta.1 integrin recognition site of the basement membrane collagen molecule [.alpha.1(IV)].sub.2 .beta.2(IV)," EMBO J. 12(12):4795-4802 (Dec., 1993).
Elices, M.J. et al., "Receptor Functions for the Integrin VLA-3: Fibronectin, Collagen, and Laminin Binding Are Differentially Influenced by ARG-GLY-ASP Peptide and by Divalent Cations," J. Cell. Biol. 112(1):169-181 (Jan., 1991).
Emini, E.A. et al., "Induction of Hepatitis A Virus-Neutralizing Antibody by a Virus-Specific Synthetic Peptide," J. Virol. 55(3):836-839 (Sep., 1985).
Gullberg, D. et al., "Analysis of .alpha..sub.1 .beta..sub.1, and .alpha..sub.3 .beta..sub.1 integrins in cell-collagen interactions: identification of conformation dependent .alpha..sub.1 .beta..sub.1 binding sites in collagen type I," EMBO J. 11(11):3865-3873 (Nov., 1992).
Hemler, M.E., "VLA Proteins in the Integrin Family: Structures, Functions, and Their Role on Leukocytes," Annu. Rev. Immunol. 8:365-400 (1990).
Hynes, R.O., "Intergrins: Versatility, Modulation, and Signaling in Cell Adhesion," Cell 69:11-25 (Apr., 1992).
Kamata, T. et al., "Identification of Putative Ligand Binding Sites within I Domain of Integrin .alpha.2.beta.1 (VLA-2, CD49b/CD29)," J. Biol. Chem. 269(13):9659-9663 (Apr., 1994).
Kamata, T. and Y. Takada, "Direct Binding of Collagen to the I Domain of Integrin .alpha.2.beta.1 (VLA-2, CD49b/CD29) in a Divalent Cation-independent Manner," J. Biol. Chem. 269(42):26006-26010 (Oct., 1994).
Kern, A. et al., "The Role of the I Domain in Ligand Binding of the Human Integrin .alpha..sub.1 .beta..sub.1," J. Biol. Chem. 269(36):22811-22816 (Sep., 1994).
Koivunen, E. et al., "Selection of Peptides Binding to the .alpha..sub.5 .beta..sub.1 Integrin from Phage Display Library," J. Biol. Chem 268(27):20205-20210 (Sep., 1993).
Kyte, J. and R.F. Doolittle, "A Simple Method for Displaying the Hydropathic Character of a Protein," J. Mol. Biol. 157:105-132 (May, 1982).
Michishita, M. et al., "A Novel Divalent Cation-Binding Site in the A Domain of the .beta.2 Integrin CR3 (CD11b/CD18) Is Essential for Ligand Binding," Cell 72:857-867 (Mar., 1993).
Paine, M.J.I. et al., "Purification, Cloning, and Molecular Characterization of a High Molecular Weight Hemorrhagic Metalloprotease, Jararhagin, form Bothrops jararaca Venom," J. Biol. Chem. 267(32):22869-22876 (Nov., 1992).
Pfaff, M. et al., "Integrin and Arg-Gly-Asp Dependence of Cell Adhesion to the Native and Unfolded Triple Helix of Collagen Type VI," Exp. Cell Res. 206:167-176 (May, 1993).
Ruoslahti, E., "Integrins," J. Clin. Invest. 87:1-5 (Jan., 1991).
Shih, D.-T. et al., "Structure/Function Analysis of the Integrin .beta.1 Subunit by Epitope Mapping," J. Cell. Biol. 122(6):1361-1371 (Sep., 1993).
Staatz, W.D. et al., "Identification of a Tetrapeptide Recognition Sequence for the .alpha..sub.2 .beta..sub.1 Integrin in Collagen," J. Biol. Chem. 266(12):7363-7367 (Apr., 1991).
Takada, Y. and M.E. Helmer, "The Primary Structure of the VLA-2/Collagen Receptor .alpha..sup.2 Subunit (Platelet GPIa): Homology to Other Integrins and the Presence of a Possible Collagen-binding Domain," J. Cell Biol. 109:397-407 (Jul., 1989).
Tuckwell, D. et al., "Integrins .alpha.2 I-domain is a binding site for collagens," J. Cell Sci. 108: 1629-1637 (Apr., 1995).
Vihinen, P. et al., "Integrin .alpha.2.beta.1 in Tumorigenic Human Osteosarcoma Cell Lines Regulates Cell Adhesion, Migration, and Invasion by Interaction with Type I Collagen," Cell Growth & Differentiation 7(4):439-447 (Apr., 1996).
Vogel, B.E. et al., "A Novel Integrin Specificity Exemplified by Binding of the .alpha..sub.v .beta..sub.5 Integrin to the Basic Domain of the HIV Tat Protein and Vitronectin," J. Cell. Biol. 121(2):461-468 (Apr., 1993).
Heino Jyrki
Ivaska Johanna
Kapyla Jarmo
BioTie Therapies Ltd.
Burke Julie
LandOfFree
Integrin binding peptide and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin binding peptide and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin binding peptide and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-663887